[18F]FDOPA PET and clinical features in parkinsonism due to manganism

被引:71
|
作者
Racette, BA
Antenor, JA
McGee-Minnich, L
Moerlein, SM
Videen, TO
Kotagal, V
Perlmutter, JS
机构
[1] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Amer Parkinson Dis Assoc, Adv Ctr Parkinson Res, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA
[4] Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA
关键词
Parkinson's disease; manganese; PET;
D O I
10.1002/mds.20381
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Manganese exposure reportedly causes a clinically and pathophysiologically distinct syndrome from idiopathic Parkinson's disease (PD). We describe the clinical features and results of positron emission tomography with 6-[F-18]fluorodopa ([F-18]FDOPA PET) of a patient with parkinsonism occurring in the setting of elevated blood manganese. The patient developed parkinsonism associated with elevated serum manganese from hepatic dysfunction. [F-18]FDOPA PET demonstrated relatively symmetric and severely reduced [F-18]FDOPA levels in the posterior putamen compared to controls. The globus pallidum interna had increased signal on T1-weighted magnetic resonance imaging (MRI) images. We conclude that elevated manganese exposure may be associated with reduced striatal [F-18]FDOPA uptake, and MRI may reveal selective abnormality within the internal segment of the pallidum. This case suggests that the clinical and pathophysiological features of manganese-associated parkinsonism may overlap with that of PD.
引用
收藏
页码:492 / 496
页数:5
相关论文
共 50 条
  • [1] Optimization of [18F]-FDOPA Brain PET Acquisition Times for Assessment of Parkinsonism in the Clinical Setting
    Keir, Graham
    Mashriqi, Faizullah
    Caravella, Christopher
    Clouston, Sean A. P.
    Rini, Josephine N.
    Franceschi, Ana M.
    AMERICAN JOURNAL OF NEURORADIOLOGY, 2024, : 781 - 787
  • [2] [18F]FDOPA PET and clinical features in a Parkinson's disease patient with manganese exposure
    Racette, BA
    Antenor, J
    Kotagal, V
    Videen, T
    Moerlein, S
    Goldman, J
    MOVEMENT DISORDERS, 2002, 17 : S108 - S108
  • [3] Comparison of 6-[18F]FDOPA PET with Nigrosome 1 detection in patients with parkinsonism
    Enrico Michler
    Daniel Kaiser
    Kiriaki Eleftheriadou
    Björn Falkenburger
    Jörg Kotzerke
    Sebastian Hoberück
    EJNMMI Research, 11
  • [4] Comparison of 6-[18F]FDOPA PET with Nigrosome 1 detection in patients with parkinsonism
    Michler, Enrico
    Kaiser, Daniel
    Eleftheriadou, Kiriaki
    Falkenburger, Bjorn
    Kotzerke, Jorg
    Hoberuck, Sebastian
    EJNMMI RESEARCH, 2021, 11 (01)
  • [5] Update on the Role of [18F]FDOPA PET/CT
    Stormezand, Gilles N.
    de Meyer, Eline
    Koopmans, Klaas Pieter
    Brouwers, Adrienne H.
    Luurtsema, G.
    Dierckx, Rudi A. J. O.
    SEMINARS IN NUCLEAR MEDICINE, 2024, 54 (06) : 845 - 855
  • [6] The impact of dopamine on aggression: An [18F]FDOPA PET study
    Vernaleken, Ingo
    Schlueter, Thorben
    Dautzenberg, Kai
    Schmaljohann, Joern
    Winz, Oliver
    Mottaghy, Felix
    Gruender, Gerhard
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [7] Incidental meningioma detected with [18F]-FDOPA PET/CT
    Stormezand G.N.
    Glaudemans A.W.J.M.
    Slart R.H.J.A.
    Dierckx R.A.J.O.
    European Journal of Hybrid Imaging, 2 (1):
  • [8] [18F]FDG PET and [18F]FP-CIT PET studies in Atypical Parkinsonism
    Kim, Su-Jeong
    Lee, Chong
    MOVEMENT DISORDERS, 2014, 29 : S89 - S89
  • [9] Does small cell lung carcinoma take-up [18F]-FDOPA and does [18F]-FDOPA PET add valuable information to [18F]-FDG PET? Preliminary results.
    Jacob, T
    Younsi, N
    Grahek, D
    Kerrou, K
    Montravers, F
    Aides, N
    Talbot, JN
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 391P - 391P
  • [10] Differential diagnosis of parkinsonism with [18F]fluorodeoxyglucose and PET
    Antonini, A
    Kazumata, K
    Feigin, A
    Mandel, F
    Dhawan, V
    Margouleff, C
    Eidelberg, D
    MOVEMENT DISORDERS, 1998, 13 (02) : 268 - 274